Research and informational content only. Not medical advice. Many peptides discussed on this site are not approved for human use.
Epitalon
Khavinson BioregulatorAlso known as: Epithalon · Epithalone · Epitalone · AEDG peptide · Ala-Glu-Asp-Gly
Animal Only
Essentially all Epitalon evidence traces to a single research group: Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology, which has published 100+ papers on bioregulator peptides over 20+ years. Until 2025, no genuinely independent international group had replicated any Epitalon experimental finding. Al-Dulaimi, Thomas, Matta & Roberts at Brunel University London (Biogerontology, March 2025; PMID 40908429) published the first independent cell-line study, confirming hTERT / telomerase upregulation in normal cells AND discovering that in cancer cell lines Epitalon extends telomeres via the alternative lengthening of telomeres (ALT) pathway. The ALT finding in cancer cells has unresolved safety implications and is editorially important. SECOND CRITICAL FRAMING: the mortality-reduction cohort data cited for Epitalon in secondary sources actually used EPITHALAMIN, the complex bovine pineal polypeptide extract, not pure synthetic Epitalon. Epithalamin contains multiple peptides; Epitalon (AEDG) is the tetrapeptide Khavinson's group characterized as the putative minimal active fraction. Effects of the complex extract cannot be automatically attributed to the synthetic tetrapeptide. The animal_only tier reflects the combination of in vitro telomerase evidence (now with one independent replication in cell lines) and controlled animal lifespan and tumor studies. The evidence is limited to animal and in vitro studies.
The mortality-reduction data often cited for Epitalon actually used Epithalamin, a different compound
The widely-cited mortality-reduction cohort data (n=266, 6 years, 1.6-1.8-fold all-cause mortality reduction; 2.5-fold when combined with Thymalin; 4.1-fold with annual combined treatment), the single most impressive numbers in Epitalon's entire literature, came from a study that used EPITHALAMIN, not pure synthetic Epitalon. Epithalamin is a complex polypeptide extract isolated from bovine pineal glands; it contains multiple peptides and is not the same compound as Epitalon. Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology characterized Epitalon (the tetrapeptide AEDG) as the putative minimal active fraction of Epithalamin, but no published study directly compares the two side-by-side for any outcome. Secondary sources, vendor marketing, and longevity-community content routinely conflate them. The honest reading: effects of the complex extract cannot be automatically attributed to the synthetic tetrapeptide. The strongest numbers commonly attached to Epitalon's name are, strictly, data about something else.
For laboratory research use only. Not for human or animal consumption.
Evidence Tier
Animal Only
Mol. Weight
390.35 Da
Last Reviewed
Apr 23, 2026
Claimed benefits by evidence tier
Column header colour matches the tier
Animal Only3
- Reduced cancer incidence
- Extended maximum lifespan
- Improved glucose tolerance / insulin sensitivity
Anecdotal1
- Anti-aging / biological age reversal
Unsupported2
- Cognitive protection / Alzheimer's prevention
- Athletic performance enhancement
About this peptide
Plain English
Epitalon is a very short synthetic peptide, just four amino acids long, developed in the 1990s by Russian researchers looking for the active component inside a bovine pineal gland extract (Epithalamin) that appeared to have life-extending effects in animals. The pineal gland produces melatonin, which regulates sleep, and the researchers also found Epitalon could influence telomerase, an enzyme that affects the protective caps on chromosomes (telomeres) that shorten as cells divide. Epitalon is sold in research markets as a lyophilized powder for research use only. Two important caveats dominate this profile: (1) essentially all experimental data comes from Khavinson's St. Petersburg research group, with no independent replication until a single British cell-line study in 2025; and (2) the striking mortality-reduction numbers often cited for Epitalon come from cohort work that used Epithalamin, the complex bovine extract, not pure synthetic Epitalon. They're not the same compound.
Technical
Epitalon (Ala-Glu-Asp-Gly; C14H22N4O9; MW 390.35 g/mol; CAS 307297-39-8; PubChem CID 219042) is a synthetic tetrapeptide classified as a Khavinson-family bioregulator peptide. Proposed mechanisms include: (1) upregulation of hTERT (human telomerase reverse transcriptase) gene expression, increasing telomerase enzymatic activity and extending telomere length in normal somatic cells; (2) in cancer cell lines specifically, telomere extension via the alternative lengthening of telomeres (ALT) pathway, a homologous-recombination-based telomerase-independent mechanism (Al-Dulaimi 2025); (3) preferential binding to methylated cytosine and to linker histone H1.3 and H1.6 subtypes, suggesting epigenetic regulation via chromatin structure; (4) stimulation of pineal melatonin synthesis in models with low baseline melatonin, likely via an incompletely characterized intracellular signalling pathway involving AANAT transcription. In vitro and animal data are substantial relative to most novel peptides, but independent international replication remained essentially absent until 2025, and evidence is limited to animal and in vitro studies. Tetrapeptides are typically degraded by serum peptidases within minutes; no pharmacokinetic study has published absorption, distribution, metabolism, excretion, half-life, or tissue penetration for systemically administered Epitalon in any model. Whether the in vitro findings translate to physiologically meaningful concentrations at cell nuclei in vivo is unknown.
Mechanism of action
hTERT promoter activation → telomerase upregulation → telomere elongation (normal cells)
Epitalon is proposed to bind the promoter region of the hTERT gene (encoding telomerase reverse transcriptase), increasing hTERT mRNA transcription, catalytic telomerase enzyme activity, and consequent telomere elongation in normal somatic cells. The DNA-binding specificity for methylated cytosine has been proposed as the molecular basis. Foundational data: Khavinson 2003 in vitro study in human fetal fibroblasts and peripheral blood lymphocytes (cell culture only). Independent replication arrived in 2025 when Al-Dulaimi et al. at Brunel University London confirmed hTERT mRNA upregulation and telomerase activity increase in normal cell lines (HMEC, IBR.3), the first non-Khavinson replication in 22 years of the Epitalon literature. No in vivo pharmacokinetic or pharmacodynamic data confirms the proposed mechanism translates to living organisms.
Alternative Lengthening of Telomeres (ALT) activation in cancer cells
The Al-Dulaimi 2025 study uncovered a cell-type-specific divergence. In breast cancer cell lines (21NT, BT474, HER-2+), Epitalon extended telomeres primarily through ALT, a homologous-recombination-based, telomerase-independent pathway, even while hTERT mRNA increased. ALT is a known telomere-maintenance mechanism used by approximately 10–15% of human cancers. The mechanistic basis for this normal-vs-cancer divergence is not yet understood, and the safety implications are ambiguous: ALT activation in pre-malignant or malignant cells could, in principle, facilitate replicative escape from senescence. Animal data on the other hand (Anisimov 2002 HER-2/neu transgenic mice) paradoxically showed anti-tumor effects. The apparent tension between a pro-ALT mechanism in cancer cell lines and an anti-tumor outcome in animal models has not been resolved.
Pineal melatonin synthesis modulation in preclinical models
Epitalon is proposed to stimulate the pineal gland's synthesis of melatonin, which declines with age. In primate models and uncontrolled observational work by Khavinson's group, administration was associated with increased nighttime melatonin at low baseline; animals or subjects with normal baseline showed a tendency toward decrease (bidirectional effect consistent with a regulatory molecule). The intracellular signalling pathway, possibly involving cAMP and downstream AANAT (arylalkylamine N-acetyltransferase) transcription, is not well characterized. IMPORTANT: the 2004 Khavinson melatonin paper uses Epithalamin (the extract) more prominently than pure Epitalon in some comparisons.
Epigenetic / chromatin modulation via histone H1 binding
Epitalon has been reported to bind linker histone H1.3 and H1.6 and methylated cytosine residues, potentially influencing chromatin structure and downstream gene expression. In lymphocytes from aged cell donors, Epitalon induced decondensation of pericentromeric heterochromatin. In vitro only; no in vivo confirmation. Khavinson group data.
Antioxidant activity in cell and wound-healing models
Epitalon has demonstrated antioxidant properties in cell-culture and animal models, attributed partly to its glutamic acid and aspartic acid residues. A 2025 in vitro model of diabetic retinopathy reported enhanced wound healing with Epitalon, partly attributed to reduced oxidative stress. In vitro and animal only; no human wound-healing or antioxidant outcome trial has been conducted.
All mechanistic data comes from cell lines or rodent/primate models, predominantly from the Khavinson research group at the St. Petersburg Institute of Bioregulation and Gerontology. The 2025 Brunel University study is the first genuinely independent cell-line replication of telomerase upregulation and is the most important scientific development in Epitalon's 22+ year literature. However, even the Brunel study is in vitro. No pharmacokinetic study has confirmed that systemically administered Epitalon reaches the nucleus of relevant cells at concentrations sufficient to drive the proposed epigenetic or telomerase-regulatory mechanisms in any in vivo model. Tetrapeptides are typically degraded by serum peptidases within minutes, and no published PK data exists for any route of administration. Mechanism plausibility is not efficacy evidence.
Key studies
Independence warning: most research for this peptide originates from a single research group. Replication by independent groups is limited.
Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells (2003)
Khavinson VKh, Bondarev IE, Butyugov AA · Bulletin of Experimental Biology and Medicine 135(6):590–592
- Participants
- In vitro, human fetal fibroblasts and adult peripheral blood lymphocytes (cell cultures, NOT human subjects).
- Methodology
- Cell culture; telomerase activity assay (TRAP); Southern blot for telomere length measurement. No control institution; no independent lab.
- Result
- Epitalon induced hTERT catalytic subunit expression, measurable telomerase activity, and telomere elongation in fibroblasts that were initially telomerase-negative.
Honest read
Critical caveat: the 'human cells' framing in the title has misled many secondary sources into treating this as human-subject data. It is a cell-culture study. Conducted entirely within Khavinson's own institute; published in the journal the institute routinely publishes in. Sample sizes (passage numbers, replicates) not reported with modern rigor. Authors are the inventors and primary promoters of Epitalon. No independent replication occurred for 22 years until Brunel 2025. This is the foundational in vitro telomerase paper for Epitalon.
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (2025)
Al-Dulaimi A, Thomas NE, Matta C, Roberts S · Biogerontology (Springer)
- Participants
- In vitro, human breast cancer cell lines (21NT, BT474), normal mammary epithelial cells (HMEC), normal fibroblasts (IBR.3).
- Methodology
- Multiple Epitalon concentrations tested; qPCR for hTERT mRNA; TRAP telomerase activity assay; telomere length by qPCR and immunofluorescence; ALT pathway marker analysis; dose-response.
- Result
- In normal cells, Epitalon upregulated hTERT mRNA and telomerase activity in a dose-dependent manner, extending telomeres. In cancer cell lines, telomere extension occurred primarily through ALT (not hTERT-dependent), even as hTERT mRNA increased.
Honest read
The single most important scientific development in Epitalon's 22+ year history. First genuinely independent (non-Khavinson, non-Russian) published experimental study, authors at Brunel University London with no stated Khavinson-institute affiliation. Confirms the telomerase-upregulation mechanism in normal cells AND discovers cell-type-specific divergence: in cancer cell lines, ALT (alternative lengthening of telomeres) becomes the dominant telomere-extension mechanism. ALT is a known telomere-maintenance mechanism used by approximately 10–15% of human cancers; its activation by Epitalon in cancer cell lines raises an unresolved safety question for individuals with pre-malignant or malignant cells. Still in vitro, translational relevance to human in vivo aging is unknown. A preprint was also posted on Research Square before peer review. Correction notice (PMID 41240216) issued; core data intact.
Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice (2002)
Anisimov VN, Khavinson VKh, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C · International Journal of Cancer 101(1):7–10
- Participants
- Female HER-2/neu transgenic mice (spontaneous mammary tumor model).
- Methodology
- Controlled animal experiment; subcutaneous Epitalon injection; compared to vehicle control; histological tumor assessment.
- Result
- Epitalon-treated mice showed significantly reduced breast adenocarcinoma incidence, fewer lung metastases (1.6x reduction), fewer multiple tumors (2x reduction), and 3.7-fold lower HER-2/neu mRNA expression in tumors compared to controls.
Honest read
Animal study in a cancer-predisposed transgenic model. Published in a respected international journal (International Journal of Cancer), lending more credibility than most Epitalon papers. Lead author Anisimov was at N.N. Petrov Oncology Institute, a different institution from the Khavinson institute, which moderately reduces but does not eliminate single-group concern. Mechanistic explanation for anti-tumor effect is not established, and the apparent tension with the 2025 Brunel ALT-in-cancer-cells finding is unresolved. No human cancer trial has followed.
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice (2003)
Anisimov VN, Khavinson VKh, Alimova IN, et al. · Biogerontology 4(4):193–202
- Participants
- Female Swiss-derived SHR mice; treatment began at 3 months age, continued monthly until death.
- Methodology
- Controlled animal experiment with survival endpoint; estrous cycle monitoring; chromosome aberration analysis; histological tumor assessment.
- Result
- 12.3% maximum lifespan extension in treated cohort; 13.3% increase in lifespan of last-10% survivors; 6-fold reduction in leukemia incidence; no effect on total solid tumor incidence; slowed age-related reproductive decline; reduced bone marrow chromosome aberrations 17%.
Honest read
Animal data only. Historical precedent: mouse lifespan extension has translated imperfectly to human longevity outcomes (rapamycin, caloric restriction). 6-fold leukemia reduction is striking and biologically plausible given Epitalon's proposed immune effects, but has not been replicated. Khavinson is a co-author, maintaining single-group concentration concerns.
Research timeline
- 1973
Vladimir Khavinson and colleagues at the St. Petersburg Military Medical Academy begin isolation and characterization of organ-specific polypeptide bioregulators, including Epithalamin (bovine pineal extract) and Thymalin (thymus extract). Research program spans the late 1970s and 1980s.
- 1990
In the 1990s, Khavinson's group characterizes Epitalon as the putative tetrapeptide active fraction of Epithalamin; chemical synthesis of AEDG is established. Animal (rodent) lifespan studies begin.
- 2001
Khavinson & Razumovsky publish open-label uncontrolled retinitis pigmentosa study (n=162) reporting 90% clinical improvement. No control group, no blinding; methodologically weak and not independently replicated.
- 2002
Anisimov, Khavinson et al. publish in International Journal of Cancer, Epitalon inhibits mammary tumor development in HER-2/neu transgenic mice. First Epitalon paper in a respected international (non-Russian) journal.
- 2002
Khavinson publishes 'Peptides and Ageing' review in Neuro Endocrinology Letters synthesizing Khavinson group data, including the cited n=266 elderly mortality cohort. CRITICAL: the cohort used EPITHALAMIN (extract), not pure Epitalon.
- 2003
Khavinson et al. publish in Bulletin of Experimental Biology and Medicine, Epithalon induces telomerase activity and telomere elongation in human somatic cells (first published telomerase data, in vitro). Conducted entirely within the Khavinson institute.
- 2003
Anisimov et al. publish SHR mouse lifespan study in Biogerontology, maximum lifespan extension 12–13%, 6-fold leukemia reduction. Animal data.
- 2004
Khavinson et al. publish melatonin study in Neuroendocrinology Letters and chromatin remodelling / histone H1 work (both in vitro and preclinical models). Primate melatonin/cortisol work also published in this period.
- 2017
Epitalon first detected as a naturally occurring component in physiological pineal gland extract, confirming it is not purely synthetic.
- 2021
Epitalon enters formal regulatory review processes in several jurisdictions, classified among peptide substances under scrutiny due to insufficient published safety and efficacy data.
- 2025
March 2025, Al-Dulaimi, Thomas, Matta & Roberts (Brunel University London) publish in Biogerontology the FIRST GENUINELY INDEPENDENT EXPERIMENTAL STUDY in Epitalon's 22+ year history. Confirms hTERT upregulation and telomerase activity in normal cell lines; discovers ALT (alternative lengthening of telomeres) activation in cancer cell lines, a mechanistic finding with unresolved safety implications. Correction notice (PMID 41240216) issued; minor, core data intact.
- 2025
MDPI overview article (PMC11943447) synthesizes Epitalon literature; authors' affiliations not independently verified for Khavinson-group ties at verification time. In vitro diabetic-retinopathy wound-healing work (PMC12356729) also published, in vitro antioxidant data.
- 2026
Ongoing regulatory review of Epitalon (free base and acetate) continues; Epitalon remains without approval or positive listing in any major jurisdiction. The compound is sold by research-chemical vendors as research use only.
What we don't know
- In vivo pharmacokinetics, no published study describes what happens to systemically administered Epitalon in any in vivo model: absorption, distribution, metabolism, excretion, half-life, or tissue penetration. Tetrapeptides are typically degraded by serum peptidases within minutes.
- Oral bioavailability, no data. Short peptides are generally degraded in the GI tract before absorption; vendors selling oral Epitalon have no published evidence supporting this route.
- Long-term safety, no multi-year controlled safety study has been conducted in any model beyond the animal lifespan studies from Khavinson's group. Long-term safety in any species beyond rodent is uncharacterized.
- Whether in vitro telomere effects translate in vivo, demonstrating telomere elongation in cell culture does not establish that the same effect occurs in living organisms at achievable tissue concentrations.
- Optimal concentration in vitro, the nonlinear dose-response observed in some studies (lower concentrations sometimes producing stronger effects than higher) has no mechanistic explanation.
- Interaction data, no published interaction data for any concomitant substance in any model.
- Cancer safety, the theoretical concern (telomerase activation promoting tumor growth) and the concern from Al-Dulaimi 2025 (ALT activation in cancer cell lines) have not been systematically evaluated beyond in vitro and animal studies. Animal data (Anisimov 2002 HER-2/neu, Anisimov 2003 SHR) is paradoxically reassuring but not definitive.
- Independent replication, every published preclinical and observational study comes exclusively from Khavinson's group or closely affiliated Russian centers. The 2025 Brunel study is the first genuinely independent replication and it is in vitro only.
- N-Acetyl Epitalon Amidate pharmacology, the modified form (N-terminal acetylation, C-terminal amidation) is sold commercially under the premise of improved metabolic stability, but no comparative in vivo pharmacokinetic or efficacy study exists demonstrating superior performance vs unmodified Epitalon.
- Mechanism specificity, whether the proposed mechanisms (hTERT upregulation, H1 binding, melatonin stimulation, ALT activation) are CAUSALLY linked to any observed clinical outcomes, or whether they are parallel observations, has not been established.
- Cell-type-specific ALT activation implications, the Al-Dulaimi 2025 finding that Epitalon preferentially activates ALT in cancer cell lines (a telomerase-independent pathway used by approximately 10-15% of cancers) has unresolved safety implications that no follow-up study has addressed.
- Epitalon vs Epithalamin comparison, no published study directly compares the synthetic tetrapeptide and the complex bovine pineal extract side-by-side in any outcome. Many claims rest on Epithalamin data extrapolated to Epitalon without justification.
Stability & handling
- Lyophilized shelf life
- Typically 24–36 months at −20°C sealed and desiccated (vendor-derived; no peer-reviewed stability study specific to Epitalon identified).
- Lyophilized storage
- Freeze at −20°C (long-term) or 4°C (short-term, up to 12–24 months if unopened, desiccated, light-protected). Protect from moisture and UV light. Warm sealed vials to room temperature before opening to prevent moisture condensation entering the vial, Epitalon is hygroscopic and the lyophilized powder degrades rapidly on exposure to atmospheric moisture.
- Reconstitution diluents
- Bacteriostatic water for injection (0.9% benzyl alcohol in sterile water), standard for research use, Sterile water for injection, Dilute acetic acid (0.1–1%), sometimes used to aid solubility
- Reconstituted (refrigerated)
- Approximately 28 days at 4°C with bacteriostatic water (vendor convention).
- Reconstituted (room temp)
- Not recommended beyond 24–48 hours.
- OK to refreeze
- No
- Light sensitive
- Yes, protect from light
Epitalon-specific QC failure modes matter for what is actually in the vial and are unusually well-documented by published analytical chemistry. (1) PUBLISHED FALSIFICATION DATA, a Belgian analytical chemistry study of falsified peptide drugs on the Belgian market found Epitalon among the FREQUENTLY FALSIFIED compounds. Falsified sample purity ranged from 5% TO 75%. Heavy metal contamination (lead, arsenic) was detected in multiple falsified peptide samples above ICH toxicity limits. This is the strongest empirical QC datum for any peptide in the ClearBatch catalog, not a theoretical risk, a measured rate. Research-peptide purchasers cannot rely on vendor claims of '99% purity' without LC-MS confirmation and heavy-metal panels. (2) ASP/GLU DEAMIDATION AND BACKBONE CLEAVAGE, aspartic acid (D) and glutamic acid (E) at positions 2 and 3 of AEDG are among the most chemically labile amino acids in peptide synthesis. Under aqueous conditions, heat, or non-neutral pH, Asp undergoes isoaspartate formation and Asp-X bond hydrolysis; Glu undergoes cyclization. These degradation products may co-elute with the parent peak on standard reversed-phase HPLC. A COA showing ≥98% HPLC purity does not exclude early-stage deamidation or isoaspartate formation. LC-MS confirmation (HRMS or MS/MS fragmentation) at the molecular ion level is the minimum meaningful QC for a Glu/Asp-containing peptide. (3) TRUNCATED SEQUENCE IMPURITIES, short tetrapeptides can carry tri- or dipeptide fragments (AG, EDG, etc.) from incomplete coupling steps. Low MW of Epitalon (390.35 g/mol) means some co-eluting impurities may be structurally similar and not resolved without high-resolution MS or orthogonal chromatography. (4) HYGROSCOPICITY, lyophilized Epitalon degrades rapidly on atmospheric moisture exposure; warming sealed vials to room temperature before opening is not cosmetic, it prevents condensation entering the vial.
Frequently asked questions
Is Epitalon the same as Epithalamin?
No. The distinction is the single most important framing fact for Epitalon. Epithalamin is a complex polypeptide extract isolated from bovine pineal glands. Epitalon (AEDG) was synthesized by Khavinson's group as the proposed minimal active fraction of Epithalamin. Epithalamin contains multiple peptides and is less chemically defined. The widely-cited cohort data reporting mortality reduction (n=266, 6 years, 1.6–4.1-fold reduction) used EPITHALAMIN, not pure synthetic Epitalon. Effects reported for Epithalamin cannot be automatically attributed to Epitalon, but most secondary sources, vendor marketing, and longevity-community content conflate them.
Does Epitalon actually extend telomeres?
In cell culture, yes. Two independent sets of experiments (Khavinson 2003; Al-Dulaimi 2025 at Brunel University London) show telomere elongation in human cell lines. Whether this translates in vivo is unknown. No in vivo study has measured telomere length before and after Epitalon administration under controlled conditions. Translating cell-line findings to in vivo outcomes requires pharmacokinetic data confirming the peptide survives serum and reaches the cell nucleus at active concentrations. That data does not exist. Tetrapeptides are typically degraded by serum peptidases within minutes.
Can Epitalon cause cancer?
This is an UNRESOLVED concern, not a confirmed risk or a confirmed non-risk. The theoretical basis for concern is real: telomerase activation is a hallmark of cancer cells. The animal data is paradoxically anti-tumorigenic (Epitalon reduced cancer incidence in mouse models, including HER-2/neu transgenic breast cancer mice). The 2025 Brunel study added new complexity: in cancer cell lines, Epitalon extended telomeres via ALT (alternative lengthening of telomeres), a telomerase-independent mechanism used by approximately 10–15% of cancers, even as hTERT mRNA increased. The safety implications of this cell-type-specific divergence are not resolved, and no controlled safety study in any species has specifically examined this question.
What is the regulatory status of Epitalon?
Epitalon has not received approval or positive listing as a drug or therapeutic from any major regulatory authority. It is sold by research chemical vendors as research use only. Regulatory review processes are ongoing in several jurisdictions. Buyers should verify current status with qualified legal or regulatory counsel in their jurisdiction before purchasing.
What's the difference between Epitalon and N-Acetyl Epitalon Amidate?
N-Acetyl Epitalon Amidate has an acetyl group added to the N-terminus and an amide added to the C-terminus, which theoretically protects the peptide from enzymatic degradation. This modification is a standard peptide-chemistry approach to improving in vivo stability. However, no published pharmacokinetic study confirms that this modified form performs better in vivo than unmodified Epitalon in any species, and no published efficacy comparison exists. The modification also changes the molecular identity, studies conducted with Epitalon cannot be automatically extrapolated to the amidate form. Anyone paying a premium for the modified form is paying for a theoretical stability advantage that has not been demonstrated experimentally.
Why does almost all the research come from one group in Russia?
Epitalon and its parent compound Epithalamin were developed and patented by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. The group has published over 100 papers on bioregulator peptides across multiple organ systems. This concentration is not unique to Russian science but is more pronounced with Epitalon than almost any other peptide in the longevity space. International researchers largely ignored this research corpus until 2025, when Al-Dulaimi et al. at Brunel University London published the first genuinely independent experimental replication. The honest implication: the evidence base is real but almost entirely unvalidated by independent parties. This does not mean the findings are wrong, it means they should carry the epistemic weight of a single research group, not a replicated scientific consensus. This profile's single_research_group_flag is TRUE.
What should I look for on an Epitalon COA?
Epitalon is the single peptide in this catalog with PUBLISHED analytical evidence of widespread falsification in research-peptide markets, a Belgian analytical chemistry study found Epitalon among frequently falsified compounds, with sample purity ranging from 5% to 75% and heavy metal contamination (lead, arsenic) above ICH toxicity limits. Minimum meaningful QC items: (1) LC-MS (preferably HRMS) confirmation of molecular mass at the expected [M+H]+ ~391.2 for free base, HPLC area-% alone is insufficient for a small peptide with a high falsification rate. (2) Heavy metal panel meeting ICH Q3D limits (Pb, As, Cd, Hg at minimum). (3) Salt form explicitly stated, free base, acetate, or TFA, and separate net peptide content (not just HPLC chromatographic purity). (4) Residual solvent panel including residual TFA. (5) Confirmation that the Asp and Glu residues have not undergone deamidation or isoaspartate formation (high-resolution MS or specific orthogonal analysis), standard RP-HPLC may not resolve these degradation products from the parent peak. A COA showing only '≥98% HPLC purity' for Epitalon without these items has not meaningfully characterized what is in the vial, and given the published falsification rate, the probability that such a vial contains something other than authentic Epitalon is non-trivial.
Last researched: Apr 23, 2026
Get the ClearBatch Report
Bi-weekly: new peptide reference profiles, third-party-tested batches, and sourcing updates.
Two emails a month. Unsubscribe anytime.